Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 191

1.

COPD Management in the Primary Care Setting.

Skolnik N, Kaplan AG, Lake T, Hayden ML, Hanania NA.

J Fam Pract. 2018 Oct;67(10 Suppl):S27-S32. No abstract available.

PMID:
30423008
2.

Targeting lipid mediators in asthma: time for reappraisal.

Diamant Z, Aalders W, Parulekar A, Bjermer L, Hanania NA.

Curr Opin Pulm Med. 2018 Nov 12. doi: 10.1097/MCP.0000000000000544. [Epub ahead of print]

PMID:
30422894
3.

The Role of Inhalation Delivery Devices in COPD: Perspectives of Patients and Health Care Providers.

Hanania NA, Braman S, Adams SG, Adewuya R, Ari A, Brooks J, Mahler DA, Ohar JA, Peters J, Sanjar S.

Chronic Obstr Pulm Dis. 2018 Apr 1;5(2):111-123. doi: 10.15326/jcopdf.5.2.2017.0168.

4.

Confronting the Challenge of COPD: What Is New in the Approaches to Diagnosis, Treatment, and Patient Outcomes.

Han MK, Hanania NA, Martinez FJ.

Chest. 2018 Oct;154(4):984-985. doi: 10.1016/j.chest.2018.08.1024.

PMID:
30290933
5.

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.

6.

Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomised studies (DOROTHEO 1 and DOROTHEO 2).

Calzetta L, Hanania NA, Dini FL, Goldstein MF, Fairweather WR, Howard WW, Cazzola M.

Pulm Pharmacol Ther. 2018 Sep 13. pii: S1094-5539(18)30182-2. doi: 10.1016/j.pupt.2018.09.007. [Epub ahead of print]

7.

Asthma COPD overlap: Impact of associated comorbidities.

Maselli DJ, Hanania NA.

Pulm Pharmacol Ther. 2018 Oct;52:27-31. doi: 10.1016/j.pupt.2018.08.006. Epub 2018 Aug 30. Review.

PMID:
30172866
8.

Clinical Approach to the Therapy of Asthma-COPD Overlap.

Maselli DJ, Hardin M, Christenson SA, Hanania NA, Hersh CP, Adams SG, Anzueto A, Peters JI, Han MK, Martinez FJ.

Chest. 2018 Aug 2. pii: S0012-3692(18)31129-2. doi: 10.1016/j.chest.2018.07.028. [Epub ahead of print] Review.

PMID:
30077690
9.

Test Performance Characteristics of the AIR, GAD-7 and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease.

Baker AM, Holbrook JT, Yohannes AM, Eakin MN, Sugar EA, Henderson RJ, Casper AS, Kaminsky DA, Rea AL, Mathews AM, Que LG, Ramsdell JW, Gerald LB, Wise RA, Hanania NA; for American Lung Association Airways Clinical Research Centers.

Ann Am Thorac Soc. 2018 Jul 9. doi: 10.1513/AnnalsATS.201708-631OC. [Epub ahead of print]

PMID:
29986152
10.

Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD.

Braman SS, Carlin BW, Hanania NA, Mahler DA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Dhand R.

Respir Care. 2018 Jul;63(7):840-848. doi: 10.4187/respcare.05717. Epub 2018 May 1.

PMID:
29717099
11.

Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices.

Dhand R, Mahler DA, Carlin BW, Hanania NA, Ohar JA, Pinto-Plata V, Shah T, Eubanks D, Braman SS.

Respir Care. 2018 Jul;63(7):833-839. doi: 10.4187/respcare.05715. Epub 2018 Mar 20.

PMID:
29559537
12.

How does race/ethnicity influence pharmacological response to asthma therapies?

Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):435-446. doi: 10.1080/17425255.2018.1449833. Epub 2018 Mar 12. Review.

PMID:
29528249
13.

Anxiety and Depression in Chronic Obstructive Pulmonary Disease: Recognition and Management.

Yohannes AM, Kaplan A, Hanania NA.

Cleve Clin J Med. 2018 Feb;85(2 Suppl 1):S11-S18. doi: 10.3949/ccjm.85.s1.03. No abstract available.

14.
15.

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.

Donohue JF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508. doi: 10.2147/COPD.S141729. eCollection 2018.

16.

Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.

Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M.

Drug Saf. 2018 May;41(5):489-509. doi: 10.1007/s40264-017-0636-9. Review.

17.

Measurement of fractional exhaled nitric oxide in real-world clinical practice alters asthma treatment decisions.

Hanania NA, Massanari M, Jain N.

Ann Allergy Asthma Immunol. 2018 Apr;120(4):414-418.e1. doi: 10.1016/j.anai.2018.01.031.

18.

Care pathways for the selection of a biologic in severe asthma.

Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, Domingo C, Hanania NA, Humbert M, Menzies Gow A, Phipatanakul W, Wahn U, Wechsler ME.

Eur Respir J. 2017 Dec 7;50(6). pii: 1701782. doi: 10.1183/13993003.01782-2017. Print 2017 Dec. No abstract available.

PMID:
29217605
19.

Trends in 30-day readmission rates after COPD hospitalization, 2006-2012.

Goto T, Faridi MK, Gibo K, Toh S, Hanania NA, Camargo CA Jr, Hasegawa K.

Respir Med. 2017 Sep;130:92-97. doi: 10.1016/j.rmed.2017.07.058. Epub 2017 Jul 26.

20.

Procalcitonin in Chronic Obstructive Pulmonary Disease Exacerbations: Is It Ready for Primetime Use?

Narendra DK, Hanania NA.

Ann Am Thorac Soc. 2017 Dec;14(12):1757-1758. doi: 10.1513/AnnalsATS.201708-673ED. No abstract available.

PMID:
29192825

Supplemental Content

Loading ...
Support Center